Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney-disease and rare-disease pipeline.Total U.S. net product sales reached $220.2 million in the third quarter, led by $200.2 million in FILSPARI sales. FILSPARI sales increased approximately 120% from a year earlier, reflecting continued growth in immunoglobulin A nephropathy (IgAN) and the first significant reven ...

Travere Therapeutics (NasdaqGM:TVTX) Q3 2026 Earnings call November 02, 2026 04:30 PM ET Company ParticipantsEric Dube - President and CEOPeter Heerma - Chief Commercial OfficerJula Inrig - Head of R&D and Chief Medical OfficerChris Cline - CFOLaura Chico - Managing Director, Co-Head of Healthcare ResearchJoe Schwartz - Managing DirectorGavin Clark-Gartner - Managing DirectorPrakhar Agrawal - Managing DirectorSadia Rahman - Vice PresidentAlex Thompson - Research Managing DirectorVamil Divan - Managing Direc ...